Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC clinical trials group BR.21 trial

Journal of Thoracic Oncology

Volumn 7, Issue 11, 2012, Pages 1653-1660

  Carbone, David P ^a   Ding, Keyue ^b   Roder, Heinrich ^c   Grigorieva, Julia ^c   Roder, Joanna ^c   Tsao, Ming Sound ^d   Seymour, Lesley ^b   Shepherd, Frances A ^d  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c BIODESIX INC   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Biomarkers; Erlotinib; Metastatic Non small cell lung cancer; Proteomics

Indexed keywords

ERLOTINIB; PLACEBO;

ADVANCED CANCER; ARTICLE; BLOOD ANALYSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VERISTRAT PLASMA TEST;

EID: 84867900616     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31826c1155     Document Type: Article

References (27)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
2. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
3. Zhu CQ, da Cunha Santos G, Ding K, et al.; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275.
4. Addison CL, Ding K, Zhao H, et al. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol 2010;28:5247-5256.
5. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multi-cohort cross-institutional study. J Natl Cancer Inst 2007;99:838-846.
6. Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in frst-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 2010;5:169-178.
7. Chung CH, Seeley EH, Roder H, et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev 2010;19:358-365.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
9. Douillard JY. Targeting the target: a step forward for the treatment of non-small-cell lung cancer. Lancet Oncol 2010;11:104-105.
10. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with geftinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-752.
11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N Engl J Med 2004;350:2129-2139.
12. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to geftinib therapy. Science 2004;304:1497-1500.
13. Fukuoka M WY, Thongprasert S, et al. Biomarker analyses from a phase III randomized, open-label, frst-line study of geftinib (G) versus carbo-platin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol 2009;27.
14. Reck M. A major step towards individualized therapy of lung cancer with geftinib: the IPASS trial and beyond. Expert Rev Anticancer Ther 2010;10:955-965.
15. Clark GM, Zborowski DM, Santabarbara P, et al.; National Cancer Institute of Canada Clinical Trials Group. Smoking history and epidermal growth factor receptor expression as predictors of survival beneft from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006;7:389-394.
16. Kim ES, Hirsh V, Mok T, et al. Geftinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818.
17. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
18. Goss GD LI, Tsao MS, O'Callaghan CJ, et al. A phase III randomized, double blind- placebo-controlled trial of the epidermal growth factor receptor inhibitor geftinib in completely resected stage 1B-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. J Clin Oncol 2010;28.
19. Yatabe Y, Mitsudomi T. Epidermal growth factor receptor mutations in lung cancers. Pathol Int 2007;57:233-244.
20. Saijo N, Takeuchi M, Kunitoh H. Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nat Rev Clin Oncol 2009;6:287-294.
21. Rosell R, Moran T, Queralt C, et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
22. Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432-433.
23. Gow CH, Chang YL, Hsu YC, et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 2009;20:696-702.
24. Carbone D P, Salmon JS, Billheimer D, et al. VeriStrat classifer for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2010;69:337-340.
25. Akerley W, Rich NT, Egbert L, Harker WG, Van Duren T, Smit J, Hoffman JM. Bevacizumab/erlotinib (BEER) as frst-line treatment for untreated advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28 (Suppl; abstract 318008).
26. Smit EF RH, Grigorieva J, Roder J, Lind JSW, Dingemans AC, Groen JHM. The proteomic classifer VeriStrat identifes advanced non-small cell lung cancer (NSCLC) patients gaining clinical beneft from treatment with frst line sorafenib and erlotinib. 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics". Berlin, Germany; 2010.
27. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-1452.